final program.qxd - Parallels Plesk Panel

More documents

Recommendations

Info

FP 3.4 Therapeutic Tat-Vaccination In Chronic HIV-Infection Daniel Zagury 1 , Hélène Le Buanec 1 , Patrick Larcier 1 , Arsene Burny 2 , Robert C. Gallo 3 1 Néovacs S.A., Université Pierre et Marie Curie, Paris, France 2 Université Libre de Bruxelles, Brussels, Belgium 3 Institute of Human Virology, University of Maryland, Baltimore, MD 21201-1192 Basic epidemiological documentation as well as non human primate experimentation prompted us to develop anti Tat therapeutic vaccine based on Tat toxoid, a protein non toxic but immunogenic HIV-1 Tat derivative. Phase I trial conducted at the Hemophiliac Bonomi Center of Milan (Pr. Gringeri) in 1997-1998 and Phase I/II trial organized by Aventis Pasteur both at Hospital St-Pierre (Pr. Clumeck, Bruxelles) and at the IHV (Pr. R. Redfield, Baltimore) in 2001-2002 showed that the Tat toxoid immunogen adjuvanted with either Seppic oil (ISA51), DcChol or Alum was safe and immunogenic. A structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Brussels (Pr. Clumeck) on the 31 vaccinees who received either a DcChol adjuvanted Tat Toxoid (n=12), a DcChol placebo (n=8) or non adjuvanted Tat Toxoid (n=11). This 2 year study showed that vaccines developing high titer of antibodies inhibiting Tat activity prolonged HAART-interruption. “ Focusing FIRST on PEOPLE “ 272 w w w . i s h e i d . c o m
PL 1 Bird Flu and Human Risk Alice Croisier, WHO (Geneva, Switzerland) Avian influenza A (H5N1) virus circulation in avian populations is posing a threat to human health. Beyond the virus's ability to cause human infection and illness, the greater threat for humanity relates to the risk for the virus to become more adapted to humans or to re-assort with another influenza A virus sub-type. Should this happen it could result in a new influenza pandemic. H5N1 is not the only influenza virus sub-type currently posing a threat for a new emergent pandemic strain, but, it is the most visible and likely at this time. It's geographical spread and range of species affected is unprecedented offering countless opportunities for virus modification. The pathogenicity of a new pandemic influenza A virus can not be predicted, nor can the timing of the pandemic, the speed of its spread or the populations which will be at most risk of serious illnesses or death. The health impact of a pandemic could range from relatively mild to severe. We can not ignore the possibility of another pandemic like that in 1918 with an estimated global human mortality of approximately 40-50 million. Regardless of ultimate severity, a pandemic vaccine probably will not be available in sufficient quantity in the early stages of a pandemic and antiviral drugs will be limited in supply. Mitigation of morbidity and mortality during the first wave of the next influenza pandemic therefore will substantially depend upon the effectiveness of non-pharmaceutical public health interventions. Pandemic preparedness begins with resource planning to facilitate optimal care for patients, case management, communication to the general public and preparations to limit hospital and community-based transmission. Recommendations may also be made to mitigate the socio-economical impact of the pandemic. There is much to learn about the determinants of spread of a pandemic and on specific interventions which are likely to mitigate it's impact. Further studies would help prepare for future pandemics. Highly pathogenic avian influenza A(H5N1) and other future pandemic threats will not go away but effective preparations can make a significant difference. FREE ORAL PRESENTATIONS “ Focusing FIRST on PEOPLE “ 273 w w w . i s h e i d . c o m
Page 2 and 3:
EDITORIAL Dear Madam, Dear Sir, It
Page 4 and 5:
PRACTICAL INFORMATION - INFORMATION
Page 6 and 7:
PROGRAM AT A GLANCE “ Focusing FI
Page 8 and 9:
WEDNESDAY JUNE 21, 2006 - MERCREDI
Page 10 and 11:
WEDNESDAY JUNE 21, 2006 - MERCREDI
Page 12 and 13:
THURSDAY JUNE 22, 2006 - JEUDI 22 J
Page 14 and 15:
THURSDAY JUNE 22, 2006 - JEUDI 22 J
Page 16 and 17:
FRIDAY JUNE 23, 2006 - VENDREDI 23
Page 18 and 19:
POSTERS PRESENTATIONS - PRESENTATIO
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
The hospital reform in progress may
Page 34 and 35:
OP 1.3 Public Health and Social Sci
Page 36 and 37:
OP 2.1 Research Priorities in HIV :
Page 38 and 39:
OP 2.3 Research Priorities In HIV I
Page 40 and 41:
OP 3.2 Interactions between HSV and
Page 42 and 43:
OP 3.4 Fertility options in HIV-inf
Page 44 and 45:
OP 3.5 Non-AIDS defining cancers in
Page 46 and 47:
OP 4.3 Update on TMC114 - Actualit
Page 48 and 49:
OP 4.5 Recent data on PA-457 Matura
Page 50 and 51:
OP 5.3 Immunology - Summary of adva
Page 52 and 53:
OP 6.2 Molecular Epidemiology of HI
Page 54 and 55:
In 1995 HIV started to spread rapid
Page 56 and 57:
Given the high HIV prevalence in ID
Page 58 and 59:
OP 6.4 The Epidemiology of HIV & ST
Page 60 and 61:
OP 7.3.1 We must switch early patie
Page 62 and 63:
OP 7.4.2 Entry inhibitors have to b
Page 64 and 65:
OP 8.2 West Nile Virus Infection in
Page 66 and 67:
First, the origin of primary introd
Page 68 and 69:
To reduce the amount of virus that
Page 70 and 71:
OP 9.1 New Developments in the Trea
Page 72 and 73:
OP 9.3 Future options in non respon
Page 74 and 75:
the consensus interferon dose (25,2
Page 76 and 77:
interferon maintenance therapy in d
Page 78 and 79:
26) Kaiser S, Hass HG, Gregor M. Su
Page 80 and 81:
OP 10.1 Progress in Microbicide Dev
Page 82 and 83:
OP 10.3 Current Advances in HIV Vac
Page 84 and 85:
dysmetabolic, functional, or organi
Page 86 and 87:
Orphans Forty-three percent of the
Page 88 and 89:
PP 1.4 Pradip Timilsena, Laxmi Pras
Page 90 and 91:
PP 1.6 Epidemiological aspects of M
Page 92 and 93:
PP 1.8 HIV transmission in The Gamb
Page 94 and 95:
PP 1.10 Evaluation of Prevalence an
Page 96 and 97:
PP 1.12 Co-morbidity of HIV, Hepati
Page 98 and 99:
PP 1.14 Screening for HIV-infection
Page 100 and 101:
PP 1.16 Low performance of HIV-1 se
Page 102 and 103:
PP 1.18 The spread of HIV-1 resista
Page 104 and 105:
PP 1.20 Study of the anti-HIV recom
Page 106 and 107:
PP 1.22 Comparative investigation o
Page 108 and 109:
PP 1.24 Foreign Citizens Admitted t
Page 110 and 111:
PP 1.26 Morbidity pattern of PLWA r
Page 112 and 113:
PP 1.28 Incidence of Atypical Mycob
Page 114 and 115:
PP 1.29 Developing Partnerships Bet
Page 116 and 117:
PP 1.31 Pakistani Youth and their R
Page 118 and 119:
PP 1.33 Model based on a quantum al
Page 120 and 121:
PP 2.2 Analysis of Full-length HIV-
Page 122 and 123:
PP 2.4 The Cobas Ampliprep/Cobas Ta
Page 124 and 125:
PP 2.6 Mutations and Polymorphisms
Page 126 and 127:
PP 2.8 Differences in the phenotypi
Page 128 and 129:
PP 2.10 Biochemical Characterizatio
Page 130 and 131:
Upon 60 minutes contact of BVDV spi
Page 132 and 133:
PP 2.13 Assessing the Contribution
Page 134 and 135:
PP 2.15 Correlation between circula
Page 136 and 137:
PP 2.17 Interface targeting peptide
Page 138 and 139:
PP 2.19 HIV-1 gene expression: less
Page 140 and 141:
PP 2.21 Vesical Cancer and Papillom
Page 142 and 143:
PP 3.2 Is Age a Complicating Factor
Page 144 and 145:
PP 3.4 Reversible HIV associated en
Page 146 and 147:
PP 3.6 Mycobacterium Ulcerans Cutan
Page 148 and 149:
PP 3.8 A Clinical Study Of 60 Patie
Page 150 and 151:
PP 3.9 HIV and Tuberculosis: Partne
Page 152 and 153:
PP 3.11 Clinicopathological compari
Page 154 and 155:
PP 3.13 Crohn's disease onset in a
Page 156 and 157:
PP 3.15 Ocular manifestations occur
Page 158 and 159:
PP 3.17 Bladder carcinoma observed
Page 160 and 161:
PP 3.19 Increasing concerns related
Page 162 and 163:
PP 3.21 Glucose intolerance and ins
Page 164 and 165:
PP 3.23 Proviral DNA and plasma vir
Page 166 and 167:
PP 3.25 Frequency, monitoring, clin
Page 168 and 169:
PP 3.27 HIV-positive cases as part
Page 170 and 171:
PP 3.29 The Effects of a Supervised
Page 172 and 173:
PP 3.31 Prevalence of depression am
Page 174 and 175:
PP 3.33 Rhinopharyngeal carcinoma w
Page 176 and 177:
PP 3.35 Large vessel damage due to
Page 178 and 179:
PP 3.37 No Interference between Syp
Page 180 and 181:
PP 3.39 Faecal flora, diarrhoea ass
Page 182 and 183:
PP 4.2 Triple therapy adherence in
Page 184 and 185:
In a hierarchical multiple regressi
Page 186 and 187:
PP 4.5 A Prospective Study of Antir
Page 188 and 189:
PP 4.7 Telephone-Based Coping Impro
Page 190 and 191:
PP 4.9 The significantly different
Page 192 and 193:
PP 4.11 Self-Evaluation Investigati
Page 194 and 195:
PP 4.13 Treatment of Kaposi's sarco
Page 196 and 197:
PP 4.15 Pharmacokinetic Interaction
Page 198 and 199:
PP 4.17 Human immunodeficiency viru
Page 200 and 201:
PP 4.19 Much More Sure than 2 Years
Page 202 and 203:
PP 4.21 No evidence of reduced viro
Page 204 and 205:
PP 4.23 The increased liver toxicit
Page 206 and 207:
PP 4.25 Rapid Oral Desensitization
Page 208 and 209:
PP 5.1 Rational design of HCV antig
Page 210 and 211:
PP 5.3 Immune restoration levels un
Page 212 and 213:
PP 5.5 Fulminant Candida albicans p
Page 214 and 215:
PP 5.7 Chronic hepatitic C-prompted
Page 216 and 217:
PP 5.9 Chronic HBV infection associ
Page 218 and 219:
PP 6.2 Broadly protective immunity
Page 220 and 221:
PP 6.4 Chikungunya arthritis sequel
Page 222 and 223: PP 6.5 Experimental determination o
Page 224 and 225: PP 6.7 Emerging Arboviruses in Turi
Page 226 and 227: PP 6.9 Ocular LOA-LOA Infection in
Page 228 and 229: PP 6.11 Prevalence of Carriers of M
Page 230 and 231: PP 6.13 Evaluation of the Prevalenc
Page 232 and 233: PP 6.15 Assessment of need of Patie
Page 234 and 235: PP 6.17 Community-acquired septicem
Page 236 and 237: PP 6.19 Multiple sclerosis managed
Page 238 and 239: PP 6.21 A serious staphylococcal kn
Page 240 and 241: PP 6.23 Comparison between Secretor
Page 242 and 243: PP 6.25 Real- Time PCR and Flow Cyt
Page 244 and 245: FP 0.2 Preclinical Development of a
Page 246 and 247: FP 0.4 Primary Resistance of a Nove
Page 248 and 249: FP 1.1 In Vivo Emergence of RANTES-
Page 250 and 251: Conclusion:Patients with HIV-1 infe
Page 252 and 253: FP 1.4 V1V2 loop length variation d
Page 254 and 255: FP 1.6 Analysis of plasma cytokines
Page 256 and 257: FP 1.8 Detection of low frequency H
Page 258 and 259: FP 1.10 Replication-Competent Platf
Page 260 and 261: FP 2.1 Long-term non-progression in
Page 262 and 263: FP 2.3 HAART in Sub-Saharan countri
Page 264 and 265: FP 2.5 Morbidity and mortality by b
Page 266 and 267: FP 2.6 Tolerability of antiretrovir
Page 268 and 269: FP 2.8 Radata - An internet-based s
Page 270 and 271: FP 3.2 Glycosylated recombinant sim
Page 274 and 275: PL 2 HIV & AIDS Research: The Light
Page 276 and 277: SS 1.1 The importance of HIV drug r
Page 278 and 279: SS 1.3 Virtual phenotype and Clinic
Page 280 and 281: SS 2.1 The Lessons we have Learned
Page 282 and 283: SS 5.2 HIV-associated facial lipoat
Page 284 and 285: SS 6.1 How to improve the use of ne
Page 286 and 287: SS 6.3 Tipranavir is a Potent Prote
Page 288 and 289: ABBOTT FRANCE Abbott is a global, b
Page 290 and 291: BOEHRINGER INGELHEIM The Boehringer
Page 292 and 293: IVAGEN IVAGEN SA, a biotechnology c
Page 294 and 295: ROCHE Headquartered in Basel, Switz
Page 296 and 297: Putting knowledge into practice VIR
Page 298: NOTES “ Focusing FIRST on PEOPLE
show all

final program.qxd - Parallels Plesk Panel

Create successful ePaper yourself

Delete template?

Save as template?